
The FDA granted FTD to opantistomig, a PD-L1/4-1BB bispecific antibody, for first-line treatment of biliary tract cancer.
Expert perspectives on the identification and management of metastatic castrate-sensitive prostate cancer in a 67-year-old man.
Case: A 67-Year-Old Male with Metastatic Castrate-Sensitive Prostate Cancer
Initial presentation
Clinical workup
Treatment and Follow-Up
Stay up to date on practice-changing data in community practice.
Subscribe




